A study identified Heat Shock Transcription Factor 1 (HSF1) as a key protein driving the renewal of leukemia stem cells in Acute Myeloid Leukemia (AML). The work is featured in Nature Communications Cancer Highlights.
Monthly Archives: November 2022
Sisu Pharma exploits cellular stress by directly targeting the transcription factor Heat Shock Factor 1 (HSF1), the Central Regulator of the heat shock response. Our HSF1 targeting platform (HI-LiTe) is being leveraged to deliver selective HSF1 degraders for oncology and therapies for use in neurodegenerative conditions and infection, providing a unique approach to treating these devastating diseases.
© 2025 . All rights reserved. Powered by Phlox Theme Privacy Policy